Page last updated: 2024-10-24

chlorambucil and ER-Negative PR-Negative HER2-Negative Breast Cancer

chlorambucil has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ma, ZY1
Wang, DB1
Song, XQ1
Wu, YG1
Chen, Q1
Zhao, CL1
Li, JY1
Cheng, SH1
Xu, JY1

Other Studies

1 other study available for chlorambucil and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    European journal of medicinal chemistry, 2018, Sep-05, Volume: 157

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Chlorambucil; Dose-Response Relations

2018